Group sequential design for randomized trials using “first hitting time” model
- Department of Epidemiology and Biostatistics University of Maryland College Park Maryland USA; ORISE, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
- Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
- Department of Epidemiology and Biostatistics University of Maryland College Park Maryland USA
Not provided.
- Research Organization:
- Oak Ridge Inst. for Science and Education (ORISE), Oak Ridge, TN (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC)
- DOE Contract Number:
- SC0014664
- OSTI ID:
- 1981435
- Journal Information:
- Statistics in Medicine, Vol. 41, Issue 13; ISSN 0277-6715
- Publisher:
- Wiley
- Country of Publication:
- United States
- Language:
- English
Similar Records
Delivery of lethal hits by cytotoxic T lymphocytes in multicellular conjugates occurs sequentially but at random times
Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial)
Consideration of the adaptive randomization allocation ratio in the presence of treatment group heteroscedasticity in clinical trials
Journal Article
·
1982
· J. Immunol.; (United States)
·
OSTI ID:6173244
Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial)
Journal Article
·
2021
· International Journal of Radiation Oncology, Biology and Physics
·
OSTI ID:23198593
+3 more
Consideration of the adaptive randomization allocation ratio in the presence of treatment group heteroscedasticity in clinical trials
Journal Article
·
2022
· Journal of Biopharmaceutical Statistics
·
OSTI ID:1982425